Stay updated on Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The study page now renders a 403 Forbidden error screen instead of the expected content, signaling blocked access to the study record with a basic header and a Home option.
    Difference
    0.5%
    Check dated 2026-09-26T17:19:55.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error, and the detailed study content is no longer visible. The standard site header/footer remains, but access to the trial record is blocked.
    Difference
    18%
    Check dated 2026-09-19T19:13:39.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    The page revision tag was updated from v3.6.5 to v3.6.6. This reflects a minor update to the page's metadata rather than changes to the visible content.
    Difference
    0.1%
    Check dated 2026-08-29T19:35:20.000Z thumbnail image
  5. Check
    62 days ago
    Change Detected
    Summary
    The page's revision was updated from v3.6.4 to v3.6.5, indicating a minor platform update. There is no indication that study content, eligibility criteria, or results text has changed.
    Difference
    0.1%
    Check dated 2026-08-08T19:02:34.000Z thumbnail image
  6. Check
    77 days ago
    Change Detected
    Summary
    Page revision updated from v3.6.3 to v3.6.4, representing a minor update to the page metadata. This change does not affect the study details, endpoints, or eligibility criteria.
    Difference
    0.1%
    Check dated 2026-07-25T10:51:28.000Z thumbnail image
  7. Check
    98 days ago
    Change Detected
    Summary
    The page now shows a newer revision line (v3.6.3) for the study documents, replacing the previous v3.6.2. This reflects an updated protocol/SAP version in the documents section.
    Difference
    0.1%
    Check dated 2026-07-03T23:53:48.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page.